Radium-223 and concomitant therapies: prospects and prudence.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Current perspectives on bone metastases in castrate-resistant prostate cancer.Cancer metastasis reviews · 2018
   Review
2. Multifaceted Roles for Macrophages in Prostate Cancer Skeletal Metastasis.Frontiers in endocrinology · 2018
   Review

Corrections and comments

• Comment on
  Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.2016

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.